M. Beatrice Forte, Cecilia Becattini, Giancarlo Agnelli
{"title":"Latest developments in antithrombotic therapy in patients with lower extremity arterial disease","authors":"M. Beatrice Forte, Cecilia Becattini, Giancarlo Agnelli","doi":"10.1016/j.rvm.2013.11.001","DOIUrl":null,"url":null,"abstract":"<div><p><span>Lower extremity arterial disease<span> (LEAD) is one of the manifestations of systemic atherosclerosis<span> causing the narrowing in the vessels of the lower limbs. Clinically it can go from an asymptomatic plaque to intermittent claudication<span> to critical limb ischemia, the most severe clinical manifestation. LEAD is associated with increased risk of other cardiovascular events such as myocardial infarction and </span></span></span></span>ischemic stroke<span><span>. The treatment of LEAD consists mainly in </span>revascularization<span> either by bypass surgery or endovascular procedures. Medical treatment also plays a major role at all stages of the disease. Amongst medical therapy anti-thrombotics are widely used for prevention of cardiovascular risk, in the prevention of re-stenosis/re-occlusion following surgical or endovascular revascularization and for symptom improvement.</span></span></p></div>","PeriodicalId":101091,"journal":{"name":"Reviews in Vascular Medicine","volume":"2 1","pages":"Pages 37-42"},"PeriodicalIF":0.0000,"publicationDate":"2014-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rvm.2013.11.001","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in Vascular Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212021113000490","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Lower extremity arterial disease (LEAD) is one of the manifestations of systemic atherosclerosis causing the narrowing in the vessels of the lower limbs. Clinically it can go from an asymptomatic plaque to intermittent claudication to critical limb ischemia, the most severe clinical manifestation. LEAD is associated with increased risk of other cardiovascular events such as myocardial infarction and ischemic stroke. The treatment of LEAD consists mainly in revascularization either by bypass surgery or endovascular procedures. Medical treatment also plays a major role at all stages of the disease. Amongst medical therapy anti-thrombotics are widely used for prevention of cardiovascular risk, in the prevention of re-stenosis/re-occlusion following surgical or endovascular revascularization and for symptom improvement.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
